Aligos TherapeuticsALGS
13F holders, Q1 2026 (March 31)At the end of Q1 2026, 34 institutions reported holding Aligos Therapeutics Inc. (ALGS) in their 13F filings, down 5 from Q4 2025. 3 opened new positions and 8 sold out. The largest holders were Deep Track Capital, LP ($3.3M), Alyeska Investment Group, L.P. ($3.1M) and Sio Capital Management, LLC ($2.4M). 3 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio), Ken Griffin (0.0% of Citadel Advisors's portfolio) and David E. Shaw (0.0% of D. E. Shaw & Co.'s portfolio).
- Company
- Aligos Therapeutics Inc.
- CUSIP
- 01626L204
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $169K |
| Exits | 8 | $582K |
All 13F filers, Q4 2025 → Q1 2026: 305,579 shares bought and 321,508 shares sold, net −15,929 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 34 holders
| Deep Track Capital, LP | 0.07% | No change | 444,110 | $3.3M |
| Alyeska Investment Group, L.P. | 0.01% | No change | 412,000 | $3.1M |
| Sio Capital Management, LLC | 0.35% | Reduce -2.6% | 327,237 | $2.4M |
| Marshall Wace, LLP | 0.00% | Reduce -0.6% | 267,135 | $2.0M |
| Bank of America Corp. | 0.00% | Add +1652.8% | 229,754 | $1.7M |
| Vanguard Capital Management LLC | 0.00% | — | 178,262 | $1.3M |
| Woodline Partners LP | 0.01% | Reduce -38.7% | 177,362 | $1.3M |
| SummitTX Capital, L.P. | 0.04% | Add +6.7% | 148,799 | $1.1M |
| Renaissance Technologies | 0.00% | Add +17.6% | 100,450 | $746K |
| Baker Bros. Advisors LP | 0.00% | No change | 83,055 | $617K |
| HHLR Advisors, LTD. | 0.03% | No change | 76,247 | $567K |
| Citadel Advisors | 0.00% | Add +4.8% | 54,311 | $404K |
| LPL Financial LLC | 0.00% | Reduce -22.0% | 51,500 | $383K |
| Geode Capital Management, LLC | 0.00% | Add +4.7% | 49,975 | $371K |
| UBS Group AG | 0.00% | Add +10081.6% | 37,061 | $275K |
| Vanguard Fiduciary Trust Co. | 0.00% | — | 28,437 | $211K |
| Two Sigma Investments, LP | 0.00% | Reduce -71.4% | 23,093 | $172K |
| Verition Fund Management LLC | 0.00% | Reduce -73.5% | 18,887 | $140K |
| XTX Topco Ltd | 0.00% | Reduce -38.4% | 14,196 | $105K |
| BlackRock, Inc. | 0.00% | No change | 13,040 | $97K |
| D. E. Shaw & Co. | 0.00% | New | 10,978 | $82K |
| Quadrature Capital Ltd | 0.00% | New | 10,822 | $80K |
| Rockefeller Capital Management L.P. | 0.00% | No change | 10,000 | $74K |
| Golden State Wealth Management, LLC | 0.00% | No change | 2,674 | $20K |
| Royal Bank of Canada | 0.00% | No change | 2,125 | $16K |
| Federation des caisses Desjardins du Quebec | 0.00% | New | 950 | $7K |
| Vanguard Global Advisers, LLC | 0.00% | — | 936 | $7K |
| Wells Fargo & Company | 0.00% | Reduce -53.3% | 700 | $5K |
| JPMorgan Chase & Co. | 0.00% | Add +120.3% | 674 | $4K |
| Morgan Stanley | 0.00% | Reduce -91.3% | 218 | $2K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +66.7% | 65 | $483 |
| SBI Securities Co., Ltd. | 0.00% | No change | 26 | $193 |
| Elevation Wealth Partners, LLC | 0.00% | No change | 4 | $30 |
| BNP Paribas Financial Markets | 0.00% | No change | 3 | $22 |
"% of holder's portfolio" is ALGS's weight in each manager's 13F, not the share of Aligos Therapeutics Inc. the manager owns.